Drew Moghanaki: The PACIFIC-5 study results are finally available
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA, shared a post on X:
“The PACIFIC-5 study results are finally available.
They provide randomized data supporting consolidation Durvalumab for patients with stage III NSCLC treated with either concurrent or sequential chemoradiotherapy.”
“Here’s the combined OS comparison suggesting some durva is better than no durva for all patients.”
“But not so fast.
It seems the primary beneficiaries of consolidation durva were those still smoking and with squamous histology, both factors INVERSELY associated with having a driver mutation.”
“And here are the safety data.”
“Let’s take a closer look at the forest plots.
What’s going on with the carbo vs cisplatin hazard ratios?”
“By “finally available”, I mean to me.
The results were originally presented on Dec 6, 2024.”
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023